Choi Hong Bae, Pyo Jung-Soo, Son Soomin, Kim Kyungdoc, Kang Guhyun
Department of Surgery, Daehang Hospital, Seoul 06699, Korea.
Department of Pathology, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu-si 11759, Korea.
Diagnostics (Basel). 2022 Mar 20;12(3):757. doi: 10.3390/diagnostics12030757.
The study is aimed to evaluate the diagnostic and prognostic role of the immunohistochemical expression of the Caudal-type homeobox transcription factor 2 (CDX2) in colorectal cancers (CRCs) through a meta-analysis. By searching relevant databases, 38 articles were eligible to be included in this study. We extracted the information for CDX2 expression rates and the correlation between CDX2 expression and clinicopathological characteristics. The estimated rates of CDX2 expression were 0.882 [95% confidence interval (CI) 0.774−0.861] and 0.893 (95% CI 0.820−0.938) in primary and metastatic CRCs, respectively. Furthermore, based on their histologic subtype, CDX2 expression rates of adenocarcinoma and medullary carcinoma were 0.886 (95% CI 0.837−0.923) and 0.436 (95% CI 0.269−0.618), respectively. There was a significant difference in CDX2 expression rates between adenocarcinoma and medullary carcinoma in the meta-regression test (p < 0.001). In addition, CDX2 expression was significantly lower in CRCs with the BRAFV600E mutation than in CRCs without mutation. Patients with CDX2 expression had better overall and cancer-specific survival rates than those without CDX2 expression. Thus, CDX2 is a useful diagnostic and prognostic marker CRCs.
本研究旨在通过荟萃分析评估尾型同源盒转录因子2（CDX2）免疫组化表达在结直肠癌（CRC）中的诊断和预后作用。通过检索相关数据库，38篇文章符合纳入本研究的条件。我们提取了CDX2表达率以及CDX2表达与临床病理特征之间相关性的信息。原发性和转移性CRC中CDX2的估计表达率分别为0.882[95%置信区间（CI）0.774−0.861]和0.893（95%CI 0.820−0.938）。此外，根据组织学亚型，腺癌和髓样癌的CDX2表达率分别为0.886（95%CI 0.837−0.923）和0.436（95%CI 0.269−0.618）。在荟萃回归分析中，腺癌和髓样癌的CDX2表达率存在显著差异（p<0.001）。此外，BRAFV600E突变的CRC中CDX2表达明显低于无突变的CRC。CDX2表达的患者比无CDX2表达的患者具有更好的总生存率和癌症特异性生存率。因此，CDX2是CRC的一种有用的诊断和预后标志物。
